Skip to main content
    L

    Ligand Pharmaceuticals Incorporated (LGND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $301.71
    -7.08 (-2.29%)

    Market Cap: $6.18B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ligand Pharmaceuticals Incorporated (LGND) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Ligand Pharmaceuticals (LGND) to earn $9.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $291.72M. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.73, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy327.3%
    Buy872.7%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 24.7% and revenue estimates rise 31.7%.

    Fiscal year ending Dec 31, 2026
    $9.58
    EPS consensus, revenue $291.72M
    Fiscal year ending Dec 31, 2027
    $11.95
    EPS consensus, revenue $384.11M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$9.58$9.25 to $9.7410$291.72M$285.80M to $297.27M10
    Dec 31, 2027$11.95$10.01 to $13.129$384.11M$355.10M to $403.13M9

    Quarterly Estimates

    The EPS consensus falls from $2.97 for the quarter ending Dec 31, 2026 to $2.36 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.97$2.38 to $3.1714$99.62M$87.81M to $109.32M13
    Mar 31, 2027$2.36$2.31 to $2.412$76.14M$76.14M to $76.14M1

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 10 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202650
    Fiscal year ending Dec 31, 202750
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.8% from $9.32.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$9.58$9.52$9.31$9.32$9.32+2.8%
    Fiscal year ending Dec 31, 2027$11.95$12.20$11.95$11.93$11.97-0.1%
    Quarter ending Mar 31, 2027$2.36$2.31$2.30$2.30$2.30+2.6%

    Frequently Asked Questions About LGND

    What is the LGND stock forecast?

    Consensus analyst estimates put Ligand Pharmaceuticals's EPS at $9.58 for the fiscal year ending Dec 31, 2026, on revenue of $291.72M. The consensus rating from 11 analysts is Buy.

    How do analysts rate LGND stock?

    Of 11 analysts covering Ligand Pharmaceuticals, 3 rate it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from LGND next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.58, with estimates from $9.25 to $9.74 from 10 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.95, with estimates from $10.01 to $13.12 from 9 analysts.

    What revenue do analysts expect from Ligand Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $291.72M, with estimates from $285.80M to $297.27M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $384.11M, with estimates from $355.10M to $403.13M.

    How many analysts cover LGND?

    11 analysts rate Ligand Pharmaceuticals stock, and 10 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.